We anticipate sustained growth in turnover as we implement our strategy of diversion.New products launch will be sustained in the core pharmaceutical business, while new product offerings in the larger health care segments and Health/Energy drinks will expand our expand our consumer base.This will allow us do more direct sales to consumers, reducing our current overdependence on 3rd parties (Distributors & Health Institutions) bringing down our receivables and vasity improving profitability and cash flow.Please click on the link below to view our Reports.
|
